A recent study by Johnson & Johnson Innovative Medicine Asia Pacific, in collaboration with Prospection, utilised patient-centric intelligence (PCI) in Japan to evaluate the persistence of endothelin receptor antagonists in pulmonary arterial hypertension (PAH) treatment.